Given the enhanced flexibility for delivering insulin and for monitoring glucose levels provided by the aforementioned technologies and the reported glycaemia benefits of diabetes technologies compared to conventional treatments,3 we hypothesize that using diabetes technologies will decrease FOH regardless of their impact on the frequency of hypoglycaemia. The gene discussed is INS; the disease is diabetes mellitus.